查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1856578

被忽视的热带疾病诊断市场：按技术、疾病类型、最终用户、应用和样本类型划分－2025-2032年全球预测

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

被忽视的热带疾病诊断市场预计到 2032 年将成长至 112.7 亿美元，复合年增长率为 6.04%。

关键市场统计数据
基准年 2024 70.4亿美元
预计年份：2025年 74.7亿美元
预测年份 2032 112.7亿美元
复合年增长率 (%) 6.04%

本文旨在介绍被忽视的热带疾病（NTL）诊断在全球卫生优先事项和商业现实中的地位，从而指南策略决策。

被忽视的热带疾病（NTDs）在许多中低收入国家仍然是持续存在的公共卫生挑战，并对卫生系统和发展伙伴提出了复杂的诊断要求。 NTDs的诊断策略必须在满足敏感性和特异性需求的同时，兼顾基础设施、人力和供应链韧性方面的限制。随着全球卫生相关人员致力于疾病的全面控制和消除，诊断发挥核心作用，它既是临床治疗的推动因素，也是为计画决策提供资讯的监测工具。

分析了影响不同卫生系统中被忽视的热带疾病诊断的关键技术、监管、规划和采购转变。

被忽视的热带疾病（NTD）诊断正经历多重变革，这些变革受到技术、规划和政策等多面向因素的驱动。分子生物学、小型化设备和数位连接的创新降低了技术门槛，使得在分散的医疗环境中也能使用更灵敏的检测方法。同时，人们越来越重视综合诊断，以支持多病种筛检和监测，这反映了提高卫生系统效率和优化资源配置的趋势。

检验了不断变化的贸易政策和关税压力如何改变诊断性筹资策略、供应链韧性以及影响专案永续性的采购权衡。

近期主要市场贸易政策和关税结构的变化，为诊断供应链带来了新的成本考量，影响了试剂、耗材和诊断硬体的筹资策略。进口关税和海关政策的变化不仅会影响到岸成本，还会影响采购週期的弹性。关税法规与区域製造能力之间的相互作用，是决定供应商在何处进行本地化生产或库存管理的关键因素。

基于全面细分的洞察，将诊断技术、疾病特定需求、最终用户场景、应用和样本类型与采用优先顺序联繫起来。

对技术、疾病类型、最终用户、应用和样本类型等细分领域的深入理解，能够清楚地揭示创新和推广路径。在技​​术领域，免疫测量（包括化学冷光检测和酵素结合免疫吸附试验）在血清学监测和确诊检测中仍然发挥着重要作用，而显微镜技术（包括萤光和光学显微镜）在许多情况下仍然是低成本诊断的基础手段。分子诊断技术（包括聚合酵素链锁反应和等温扩增检测）对低寄生虫负荷感染疾病具有高灵敏度，并在确诊过程中扮演越来越重要的角色。能够同时检测抗原和抗体的快速诊断测试，为社区筛检和即时检测决策提供了所需的便利性和速度。

影响美洲、欧洲、中东和非洲以及亚太地区诊断服务取得和实施选择的专案和营运驱动因素

区域动态持续影响专案优先事项、诊断手段的可及性和产品推广路径。在美洲，城乡差距和地方性流行区域使得将无核化热带病（NTD）诊断纳入更广泛的基层医疗服务成为必要，同时在三级医疗中心配备实验室确诊能力，并利用快速筛检工具开展远距推广。跨境协调和区域公共卫生倡议影响采购协调和数据共用实践，从而支持有针对性的消除项目。

本文旨在探讨被忽视的热带疾病诊断领域的竞争格局、合作伙伴关係和产品差异化策略。

被忽视的热带疾病（NTD）诊断领域的竞争生态系统由成熟的诊断试剂生产商、专注于特定领域的专业开发商、学术实验室以及支持验证和临床评估的合约研发机构组成。现有企业正在调整其产品组合，以满足对整合检测解决方案和数位化连接的需求，而规模较小的创新企业则倾向于专注于颠覆性平台，例如简易的等温扩增方法、新型抗原检测化学方法以及专为现场部署而设计的无需仪器的读数设备。

为製造商、资助者和专案规划者提供切实可行的建议，以使诊断创新与现场部署实际情况和专案永续性适应。

产业领导者应采取务实的多管齐下策略，使创新与实际营运相契合。首先，应优先发展那些注重稳健性、易用性以及最大限度减少对复杂低温运输和先进基础设施依赖的研发路径，从而拓宽诊断技术有效部署的环境范围。其次，应投资进行检验研究，以证明其在专案实施条件下以及在相关样本类型中的性能，从而增强采购机构和第一线医护人员的信心。

对混合方法研究途径进行了清晰的解释，该方法结合了相关人员访谈、文献综述和比较分析，为所提出的见解提供了理论基础。

本报告整合了一手和二手研究资料，结合相关人员访谈、产品性能文献、监管指导文件和实地检验研究，以三角验证的方式得出结论。一手资料包括对诊断试剂开发人员、实验室主任、地方性流行病临床医生、采购专业人员和公共卫生专案经理的结构化访谈，从定性观点分析了可用性、供应链考量和推广障碍。二级资讯来源包括关于诊断性能的同行评审文献、已发布的监管标准以及与被忽视的热带疾病（NTD）计画实施相关的国际卫生机构技术指南。

策略结论强调，务实创新、伙伴关係和采购协调是改善诊断和实现公共卫生持续成长的途径。

诊断是防治被忽视的热带疾病的关键，它既有助于个别患者的治疗，也有助于实现人群层面的计画目标。技术进步、采购惯例的改变以及对监测的日益重视，共同为弥合数十年来一直存在的诊断差距提供了机会。要充分发挥这项潜力，需要研发人员、资助者、专案执行者和监管机构齐心协力，确保产品从创新到应用的过程中，兼顾易用性、品质和供应链的韧性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 针对多种被忽视的热带疾病，快速扩展的多重即时诊断平台整合了人工智慧主导的影像分析技术，并应用于多种被忽视的热带疾病的诊断。
  • 在资源匮乏的环境中，扩大基于 CRISPR 的诊断检测方法在热带疾病病原体超灵敏检测的应用
  • 利用等温扩增技术开发携带式分子诊断设备，用于被忽视的热带感染疾病的现场监测
  • 加强公共卫生机构与生物技术公司之间的伙伴关係，以便在偏远流行地区部署下一代诊断技术。
  • 利用机器学习技术准确识别寄生虫种类的智慧型手机显微镜应用程式的出现。
  • 利用快速侧向层析免疫检测扩大社区血清学筛检项目，以早期发现被忽视的热带疾病
  • 整合云端连接诊断终端，用于即时数据收集和被忽视的热带疾病流行病学绘图
  • 用于同时定量分析血清检体中被忽视的热带病生物标记的多重ELISA试剂盒的创新
  • 监管方面的进展为高负担低收入国家的新型被忽视的热带疾病诊断工具提供了快速核准途径。
  • 扩大行动实验室网络，为热带疾病流行地区的疫情热点地区提供基于DNA的病原体检测

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 被忽视的热带疾病诊断市场（依技术划分）

  • 免疫检测
    • 化学冷光检测法
    • 酵素结合免疫吸附检测法
  • 显微镜
    • 萤光显微镜
    • 光学显微镜
  • 分子诊断
    • 等温扩增
    • 聚合酵素链锁反应
  • 快速诊断测试
    • 抗体检测
    • 抗原检测

9. 被忽视的热带疾病诊断市场（依疾病类型划分）

  • 南美锥虫病
    • 酵素结合免疫吸附检测法
    • 聚合酵素链锁反应
  • 利什曼原虫症
    • 皮肤利什曼原虫症检测
    • 利什曼原虫症检测
  • 淋巴丝虫病
    • 抗体检测
    • 层析法试验
  • 盘尾丝虫病
    • 聚合酵素链锁反应
    • 皮肤显微镜检查
  • 血吸虫病
    • 粪便显微镜检查
    • 尿抗原检测

第十章 被忽视的热带疾病诊断市场（以最终用户划分）

  • 诊所
    • 社区医疗中心
    • 基层医疗诊所
  • 诊断实验室
    • 独立实验室
    • 参考实验室
  • 医院
    • 私立医院
    • 公立医院
  • 研究所

第十一章 被忽视的热带疾病诊断市场（按应用划分）

  • 确认性检查
    • 实验室确诊检测
    • 照护现场确认
  • 筛检
    • 社区筛检
    • 大规模药物管理筛检
  • 监视
    • 流行病学监测
    • 根除后监测

第十二章 被忽视的热带疾病诊断市场（依样本类型划分）

  • 血
    • 血清血浆
    • 全血
  • 航班
    • 浓缩法
    • 直接涂片
  • 组织
    • 切片检查
    • 皮肤剪
  • 尿
    • 浓缩尿液检查
    • 直接尿液检查

13. 被忽视的热带疾病诊断市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 被忽视的热带疾病诊断市场（按类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国被忽视的热带疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • bioMerieux SA
    • QIAGEN GmbH
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • Coris BioConcept SA
Product Code: MRR-742BD5181EB6

The Neglected Tropical Diseases Diagnosis Market is projected to grow by USD 11.27 billion at a CAGR of 6.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.04 billion
Estimated Year [2025] USD 7.47 billion
Forecast Year [2032] USD 11.27 billion
CAGR (%) 6.04%

Contextual introduction that situates neglected tropical diseases diagnostics within global health priorities and operational realities to guide strategic decision making

Neglected tropical diseases (NTDs) remain a persistent public health challenge in many low- and middle-income settings, placing complex diagnostic demands on health systems and development partners. Diagnostic strategies for NTDs must reconcile the need for sensitivity and specificity with constraints in infrastructure, workforce capacity, and supply chain resilience. As global health actors pivot toward integrated disease management and elimination goals, diagnostics assume a central role both as enablers of clinical care and as surveillance instruments for programmatic decision-making.

This executive summary synthesizes current diagnostic technology trends, disease-specific testing pathways, end-user dynamics, and regional programmatic drivers that shape the evolving landscape. The intent is to provide healthcare leaders, diagnostic developers, procurement agencies, and policy makers with a concise yet comprehensive analytical foundation to support strategic planning. By framing diagnostic innovation alongside operational realities, the summary highlights where technological advances, policy shifts, and financing mechanisms intersect to accelerate-or in some cases impede-progress against NTDs.

The content emphasizes practical implications for stakeholders who must balance diagnostic performance with affordability, accessibility, and sustainability. It also underscores the interplay between point-of-care approaches and centralized laboratory confirmation, illustrating how diverse testing modalities contribute differently to case detection, surveillance, and program validation across varied epidemiological contexts.

Analysis of the pivotal technological, regulatory, programmatic, and procurement shifts reshaping diagnostics for neglected tropical diseases across diverse health systems

The diagnostic landscape for NTDs is undergoing several transformative shifts driven by converging technological, programmatic, and policy forces. Innovations in molecular biology, miniaturized instrumentation, and digital connectivity have lowered some technical barriers, enabling more sensitive assays to be used in decentralized settings. At the same time, there is an increasing emphasis on integrated diagnostics that support multi-disease screening and surveillance, reflecting a broader push for health system efficiencies and resource optimization.

Regulatory evolution and quality assurance frameworks are also reshaping product pathways. Greater attention to validation in real-world contexts, along with calls for harmonized performance standards, is prompting manufacturers and developers to design assays that meet both laboratory and point-of-care expectations. Procurement behaviors are shifting toward outcome-based and pooled purchasing mechanisms, encouraging suppliers to align product portfolios with programmatic needs rather than purely laboratory-driven specifications.

Operationally, community-level programs are demanding tests that are rapid, robust under field conditions, and deliver clear actionable outputs for frontline workers. Simultaneously, centralized laboratories continue to require high-throughput, confirmatory platforms to validate cases and support elimination verification. These dual imperatives are driving hybrid strategies that pair on-site screening with confirmatory laboratory workflows, supported by digital reporting chains that enable faster public health action and improved surveillance granularity.

Examination of how evolving trade policies and tariff pressures are altering diagnostic sourcing strategies, supply chain resilience, and procurement trade-offs for program sustainability

Recent shifts in trade policy and tariff structures in major markets have introduced new cost considerations into diagnostic supply chains, affecting sourcing strategies for reagents, consumables, and diagnostic hardware. Changes to import duties and customs practices can influence not only landed costs but also the agility of procurement cycles, which are critical when programs require rapid scale-up during outbreak responses or mass drug administration campaigns. The interplay between tariff rules and regional manufacturing capacity has become an important determinant of where suppliers choose to localize production or stock inventory.

For program planners and procurement officers, the practical implication is a reassessment of supplier portfolios and an increased focus on supply chain redundancy. Organizations are evaluating the trade-offs between single-source procurement of validated products and diversified sourcing that mitigates tariff-driven price volatility or border-related delays. In some cases, increased tariffs have accelerated conversations about regional manufacturing partnerships and technology transfer models that can insulate programs from future policy shocks.

Operationally, tariff-induced cost pressures tend to magnify the advantage of diagnostic approaches that minimize recurring imports, such as assays with longer shelf-lives, reduced cold-chain dependence, or platforms compatible with locally produced consumables. As a result, stakeholders are reexamining test selection criteria with supply chain resilience and total cost of ownership in mind, favoring solutions that balance diagnostic performance with pragmatic logistics under evolving trade conditions.

Comprehensive segmentation-driven insights that map diagnostic technologies, disease-specific needs, end-user contexts, applications, and sample types to implementation priorities

A nuanced understanding of segmentation across technology, disease type, end user, application, and sample type reveals distinct pathways for innovation and implementation. In the technology domain, immunoassays-encompassing chemiluminescence assays and enzyme-linked immunosorbent assays-remain important for serological surveillance and confirmatory testing, while microscopy approaches, including fluorescence and light microscopy, continue to serve as low-cost diagnostic backbones in many settings. Molecular diagnostics, represented by polymerase chain reaction and isothermal amplification methods, offer high sensitivity for low-parasite-burden infections and play an increasingly central role in confirmation workflows. Rapid diagnostic tests, with both antigen and antibody detection formats, provide the speed and simplicity required for community screening and point-of-care decision-making.

Disease-specific diagnostics show differentiated needs that shape product development and deployment. Chagas diagnostics frequently pair enzyme-linked immunosorbent assay and polymerase chain reaction to address both chronic serology and acute parasitemia detection, whereas leishmaniasis diagnostics bifurcate into tests optimized for cutaneous and visceral presentations. Lymphatic filariasis relies heavily on antibody detection tests alongside immunochromatographic approaches for mass screening, while onchocerciasis often requires polymerase chain reaction and skin snip microscopy methods depending on program stage. Schistosomiasis testing strategies blend stool microscopy concentration techniques with urine antigen assays to accommodate community-level mapping and individual case confirmation.

End-user contexts strongly influence acceptable product attributes. Clinics and primary care settings prioritize ease of use and minimal infrastructure requirements, community health centers need durable tests suited for outreach, diagnostic laboratories demand standardized protocols and traceability, and hospitals-both private and public-require integration with clinical workflows and laboratory information systems. Research institutes further drive innovation by evaluating novel biomarkers and validation protocols. Applications range from confirmatory laboratory and point-of-care confirmation to community screening approaches that support mass drug administration, and surveillance activities that span epidemiological monitoring through to post-elimination vigilance. Sample type considerations-blood in serum, plasma or whole blood formats, stool through concentration or direct smear, tissue from biopsies or skin snips, and urine via concentrated or direct testing-determine pre-analytical workflows and influence test design choices such as input volumes, preservation requirements, and biosafety implications.

Taken together, segmentation insights highlight where manufacturers can differentiate offerings by aligning technology platforms with disease-specific performance needs, by tailoring workflows to end-user capacity, and by optimizing sample handling to suit programmatic realities. This segmentation-driven lens helps stakeholders prioritize investments that close diagnostic gaps while ensuring practical deployability across diverse operational environments.

Regional programmatic and operational dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine diagnostic access and implementation choices

Regional dynamics continue to shape programmatic priorities, diagnostic accessibility, and product adoption pathways. In the Americas, urban-rural disparities and pockets of endemicity require a blend of laboratory confirmation capacity in tertiary centers and rapid screening tools for remote outreach, with an emphasis on integrating NTD diagnostics into broader primary care services. Cross-border coordination and regional public health initiatives influence procurement harmonization and data sharing practices that support targeted elimination programs.

Europe, Middle East & Africa presents a heterogeneous landscape where some countries possess advanced laboratory infrastructure while others face significant resource constraints. This region's priorities often include strengthening laboratory networks, building quality assurance systems, and enabling decentralized diagnostics that can function with intermittent power and limited cold-chain capacity. Regulatory environments and fragmented procurement mechanisms in parts of the region make harmonized validation and pooled purchasing attractive options for reducing duplicative costs and improving access.

Asia-Pacific exhibits a wide spectrum of epidemiological contexts, from densely populated urban centers to remote island communities. Program strategies here emphasize scalable screening modalities, integration with other endemic disease programs, and investments in local manufacturing capacity to shorten supply chains. The region's growing diagnostic manufacturing footprint and increasing public-private collaboration present opportunities to adapt technologies for both high-volume surveillance and sensitive case confirmation in low-transmission settings.

Insights into the competitive landscape, collaborative partnerships, and product differentiation strategies shaping the neglected tropical diseases diagnostics sector

The competitive ecosystem for NTD diagnostics includes a mix of established diagnostics manufacturers, specialized niche developers, academic laboratories, and contract research organizations that support validation and clinical evaluation. Established firms are adapting portfolios to address the need for integrated testing solutions and digital connectivity, while smaller innovators often focus on disruptive platforms such as simplified isothermal amplification, novel antigen detection chemistries, and instrument-free readouts designed for field deployment.

Collaborations between commercial entities and academic research centers accelerate translation of novel biomarkers into deployable assays, and partnerships with non-governmental organizations and global health donors help pilot products in real-world program settings. Contract development and manufacturing organizations play a critical role in scaling production and ensuring quality systems compliance, particularly for late-stage validation and prequalification. Procurement entities increasingly expect suppliers to demonstrate robust post-market surveillance and support mechanisms for training, quality control, and supply continuity.

For companies seeking to differentiate, investment in usability testing, end-user training materials, and digital integration capabilities can create competitive advantage. Similarly, strategic alliances that enable regional manufacturing or in-country assembly can mitigate supply chain disruption and improve access in markets where localization reduces logistical friction and supports program sustainability.

Actionable recommendations for manufacturers, funders, and program planners to align diagnostic innovation with field deployment realities and program sustainability

Industry leaders should adopt a pragmatic, multi-pronged approach that aligns innovation with implementation realities. First, prioritize development pathways that emphasize robustness, ease of use, and minimal reliance on complex cold chains or sophisticated infrastructure, thereby expanding the range of settings where diagnostics can be effectively deployed. Second, invest in validation studies that demonstrate performance in programmatic conditions and across relevant sample types to build confidence among procurement agencies and frontline providers.

Third, cultivate regional manufacturing or assembly partnerships to reduce exposure to cross-border trade disruptions and to shorten lead times for consumables and instruments. Fourth, design pricing and distribution models that reflect the total cost of ownership, including training, quality assurance, and maintenance, and engage early with procurement stakeholders to align product specifications with program budgets and policy frameworks. Fifth, incorporate digital reporting capabilities that streamline data flows from peripheral testing sites to central surveillance systems, enabling faster public health responses and more efficient program monitoring.

Finally, adopt collaborative commercialization strategies that include partnerships with non-governmental organizations, governmental programs, and research institutes to facilitate field evaluations, user feedback loops, and phased roll-outs that inform product iteration. By executing on these priorities, industry leaders can ensure that investments in technology translate into measurable improvements in case detection, surveillance quality, and programmatic impact.

Clear explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and comparative analysis to underpin the insights presented

This report synthesizes primary and secondary research, combining stakeholder interviews, product performance literature, regulatory guidance documents, and field validation studies to triangulate insights. Primary inputs include structured interviews with diagnostic developers, laboratory directors, clinicians in endemic settings, procurement specialists, and public health program managers, which provided qualitative perspectives on usability, supply chain considerations, and adoption barriers. Secondary sources comprised peer-reviewed literature on diagnostic performance, publicly available regulatory standards, and technical guidance from global health authorities related to NTD program implementation.

Analytical methods included cross-segmentation mapping to identify alignment and gaps between technology attributes and end-user needs, scenario analysis to assess supply chain and procurement sensitivities, and comparative assessment of diagnostic workflows across disease-specific contexts. Where available, real-world validation data and field study outcomes informed assessments of operational suitability. The methodology prioritized transparency by documenting data provenance, interview protocols, and criteria used for technology and product evaluation, enabling reproducibility and informed follow-up research.

Limitations include variability in published performance data across settings and the evolving nature of regulatory pathways, which require ongoing monitoring. Nonetheless, the mixed-methods approach provides a robust foundation for strategic decision-making by combining empirical evidence with practical stakeholder perspectives drawn from diverse geographic and institutional contexts.

Strategic conclusion emphasizing pragmatic innovation, partnerships, and procurement alignment as the pathway to improved diagnostics and durable public health gains

Diagnostics are central to progress against neglected tropical diseases, serving both individual patient care and population-level program objectives. The convergence of technological advances, shifting procurement practices, and heightened emphasis on surveillance creates a window of opportunity to close diagnostic gaps that have persisted for decades. Realizing this potential requires coordinated action across developers, funders, program implementers, and regulatory bodies to ensure that products move from innovation to deployment with attention to usability, quality, and supply chain resilience.

Strategic investments in regionally appropriate technologies, validation in programmatic contexts, and mechanisms that de-risk local manufacturing will accelerate access and sustainability. Moreover, integrated approaches that combine rapid screening at the community level with confirmatory laboratory workflows and strengthened data systems will enhance detection sensitivity while supporting timely public health interventions. The cumulative effect of these steps will be measurable improvements in case finding, surveillance fidelity, and the ability to validate elimination milestones in endemic regions.

Ultimately, the path forward is one of pragmatic innovation: technologies that meet field realities, partnerships that bridge development and delivery, and procurement strategies that emphasize reliability and total cost considerations. Stakeholders who align their initiatives with these principles will be best positioned to translate diagnostic advances into durable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of multiplex point-of-care diagnostic platforms integrating AI-driven image analysis for multiple neglected tropical diseases
  • 5.2. Growing adoption of CRISPR-based diagnostic assays enabling ultra-sensitive detection of tropical disease pathogens in low-resource settings
  • 5.3. Development of portable molecular diagnostic devices leveraging isothermal amplification for field-level surveillance of neglected tropical infections
  • 5.4. Increasing partnerships between public health agencies and biotech firms to deploy next-generation diagnostics in remote endemic regions
  • 5.5. Emergence of smartphone-enabled microscopy apps using machine learning to accurately identify parasite species in point-of-need scenarios
  • 5.6. Scaling up of community-based serological screening programs supported by rapid lateral flow immunoassays for early detection of NTDs
  • 5.7. Integration of cloud-connected diagnostic kiosks for real-time data collection and epidemiological mapping of neglected tropical diseases
  • 5.8. Innovation in multiplex ELISA kits for simultaneous quantification of multiple neglected tropical disease biomarkers in serum samples
  • 5.9. Regulatory advances facilitating accelerated approval pathways for novel NTD diagnostic tools in highly burdened low-income countries
  • 5.10. Expansion of mobile laboratory networks offering DNA-based pathogen detection in outbreak hotspots of tropical disease endemic areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Diseases Diagnosis Market, by Technology

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescence Assay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
  • 8.2. Microscopy
    • 8.2.1. Fluorescence Microscopy
    • 8.2.2. Light Microscopy
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Rapid Diagnostic Tests
    • 8.4.1. Antibody Detection
    • 8.4.2. Antigen Detection

9. Neglected Tropical Diseases Diagnosis Market, by Disease Type

  • 9.1. Chagas Disease
    • 9.1.1. Enzyme Linked Immunosorbent Assay
    • 9.1.2. Polymerase Chain Reaction
  • 9.2. Leishmaniasis
    • 9.2.1. Cutaneous Leishmaniasis Tests
    • 9.2.2. Visceral Leishmaniasis Tests
  • 9.3. Lymphatic Filariasis
    • 9.3.1. Antibody Detection Test
    • 9.3.2. Immunochromatographic Test
  • 9.4. Onchocerciasis
    • 9.4.1. Polymerase Chain Reaction
    • 9.4.2. Skin Snip Microscopy
  • 9.5. Schistosomiasis
    • 9.5.1. Stool Microscopy
    • 9.5.2. Urine Antigen Test

10. Neglected Tropical Diseases Diagnosis Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Health Centers
    • 10.1.2. Primary Care Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Independent Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Research Institutes

11. Neglected Tropical Diseases Diagnosis Market, by Application

  • 11.1. Confirmatory Testing
    • 11.1.1. Laboratory Confirmation
    • 11.1.2. Point Of Care Confirmation
  • 11.2. Screening
    • 11.2.1. Community Screening
    • 11.2.2. Mass Drug Administration Screening
  • 11.3. Surveillance
    • 11.3.1. Epidemiological Surveillance
    • 11.3.2. Post Elimination Surveillance

12. Neglected Tropical Diseases Diagnosis Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Serum Plasma
    • 12.1.2. Whole Blood
  • 12.2. Stool
    • 12.2.1. Concentration Technique
    • 12.2.2. Direct Smear
  • 12.3. Tissue
    • 12.3.1. Biopsy
    • 12.3.2. Skin Snip
  • 12.4. Urine
    • 12.4.1. Concentrated Urine Test
    • 12.4.2. Direct Urine Test

13. Neglected Tropical Diseases Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neglected Tropical Diseases Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neglected Tropical Diseases Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Danaher Corporation
    • 16.3.5. bioMerieux SA
    • 16.3.6. QIAGEN GmbH
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. Hologic, Inc.
    • 16.3.10. Coris BioConcept SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CO